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Electrochemotherapy is a combined modality treatment using
chemotherapy and electroporation (Mir and Orlowski, 2000).
Electroporation is a physical method, performed by application of
high voltage direct current electric pulses to cells in vitro or tissues
in vivo, to increase cell uptake of molecules such as DNA, anti-
bodies, enzymes, dyes and drugs by permeabilization of the
plasma membrane (Mir and Orlowski, 2000; Sersa, 2000). In elec-
trochemotherapy, the optimal antitumour effectiveness is achieved
when treatment is given at the time of the highest extracellular
concentration of hydrophilic chemotherapy drugs, thereby
increasing transport through plasma membrane towards the intra-
cellular targets for cytotoxicity (Mir and Orlowski, 2000). The
chemotherapeutic drugs, bleomycin and cisplatin, have proven to
be effective in electrochemotherapy of experimental tumour cells,
both in vitro and in vivo (Mir and Orlowski, 2000; Sersa, 2000)
and also in electrochemotherapy of accessible tumour nodules of
various malignancies in cancer patients (Heller et al, 2000).
Neither drugs alone nor high voltage electric pulses as single treat-
ment affected tumour growth (Heller et al, 2000; Mir and
Orlowski, 2000; Sersa, 2000). 
Antitumour effectiveness of electrochemotherapy is primarily
due to the increased uptake of the chemotherapeutic drugs 
into the tumour cells, caused by electroporation. The increased 
accumulation has been confirmed for platinum (component of
cisplatin) and radioactively labelled bleomycin into tumour cells
in vivo after treatment with electrochemotherapy (Belehradek 
et al, 1994; Cemazar et al, 1999). However, several other mecha-
nisms have been demonstrated to be involved in tumour response
to electrochemotherapy, e.g. involvement of immune system and
changes in tumour blood flow (Mir et al, 1995; Sersa et al,
1997a,b). The vascular targeting action of electrochemotherapy
was only speculated. The immune status of experimental mice was
shown to be positively correlated with the incidence of complete
responses of tumours treated with electrochemotherapy (Sersa 
et al, 1997a) and potentiation of tumour response to electro-
chemotherapy was achieved by adjuvant immunotherapy, either
with IL-2 or TNF-a (Mir et al, 1995; Sersa et al, 1997b). We have
previously shown that the application of electric pulses alone
result in substantial, but transient, reduction of tumour perfusion
(Sersa et al, 1999a) and furthermore that electrochemotherapy
with bleomycin causes rapid cessation of tumour perfusion (Sersa
et al, 1999b). In addition, electrochemotherapy prolonged entrap-
ment of cisplatin for up to 8 hours within the tumour (Cemazar 
et al, 1999). We hypothesize that the anti-tumour action of elec-
trochemotherapy may be partly due to its antivascular action. It is
our hypothesis that damage to the endothelial cells, which are elec-
troporated during application of electric pulses, leads to the reduc-
tion of tumour perfusion, which contributes to the antitumour
effectiveness of electrochemotherapy. 
The aim of the present study was to investigate the role of
endothelial cells in the antivascular action of electrochemotherapy.
The sensitivity of human microvascular endothelial cells, HMEC-
1, to electroporation with cisplatin or bleomycin was determined
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in vitro and compared to sensitivity of the cells to the treatment
with the drugs alone. 
MATERIALS AND METHODS 
Chemicals 
Cisplatin (Platamine, Pharmacia & Upjohn, Milan, Italy) was
dissolved in sterile H2O to obtain a concentration of 6.7 mM. The
final concentrations were prepared in Dulbecco’s modified Eagles
medium (D-MEM; Gibco Life Technologies, Paisley, UK).
Bleomycin (Bleo-Kyowa, Kyowa Hakko, Slough, UK) was
dissolved in D-MEM at a concentration of 10 mM. All further
dilutions were also prepared in D-MEM. Propidium iodide
(Sigma-Aldrich Company Ltd, Poole, UK) was prepared in phos-
phate-buffered saline in a concentration of 0.1 mM. 
Cells 
Human dermal microvascular endothelial cells (HMEC-1) were
generously provided by Dr FJ Candal (Center for Disease Control,
Atlanta, USA). This cell line was immortalized by transfection
with a plasmid containing simian virus 40A gene product, large T
antigen (Ades et al, 1992). HMEC-1 cells were grown as mono-
layer in D-MEM supplemented with 10% fetal calf serum (FCS,
Sigma) in a humidified incubator at atmospheric oxygen supple-
mented with 5% CO2 at 37˚C. They were routinely subcultured
twice per week. When grown in monolayer the cells exhibited
typical cobblestone morphology. 
Determination of electro-permeabilization and 
electro-sensitivity 
Electro-permeabilization of plasma membrane was measured by
cellular uptake of propidium iodide. Electro-sensitivity (survival
of cells treated with electric pulses) was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay. The cells were prepared from exponential growth phase,
trypsinized and washed twice, first in the D-MEM supplemented
with 10% FCS for inactivation of trypsin (Sigma), and then in the
serum-free D-MEM. Cell suspensions (2.2 ´ 107 cells ml–1 in
90 ml) were prepared containing 10 ml propidium iodide (100 mM)
for permeability assay or with D-MEM for MTT cytotoxicity
assay. The cells were placed between the two parallel stainless-
steel electrodes (length 6 mm, width 6 mm, gap 2 mm) connected
to the electroporator (Jouan GHT 1287, France) and subjected to 8
square wave electric pulses (pulse width 100 ms, repetition
frequency 1 Hz) of different electric field intensities, ranging from
400 to 1800 V cm–1 (Figure 1). After exposure to electric pulses,
the cells were incubated for 5 min at room temperature (24˚C).
This incubation time was shown to be the optimal, since it allows
resealing of plasma membrane and it does not affect cell viability
due to the evaporation of medium and lack of nutrients (Rols and
Teissie, 1998). To measure the propidium iodide uptake, 25 ml of
cell suspension was resuspended in 1 ml of 0.01 M phosphate
buffered saline (pH 7.4) and analysed immediately by FACSort
(Becton Dickinson, Mountain View, CA, USA). The percentage of
stained cells was determined in comparison to the control cells that
were not subjected to electric pulses. The electro-sensitivity of
cells was determined by MTT assay performed 3 days after plating
in 96-well microtitre plates. Briefly, at the end of incubation time
MTT solution (25 ml of 5 mg ml–1 solution) was added to each well
and the microtitre plates were further incubated for 3 h at 37˚C.
The formed formazan crystals were dissolved in 100 ml of
dimethyl sulphoxide (Sigma). The microtitre plates were shaken
for 99 s to ensure adequate solubilization and the absorbance of
the resulting solution was measured at 570 nm using an Anthos
microplate reader (Anthos Labtec, Salzburg, Austria). The
survival of cells treated with electric pulses was presented as a
percentage of the absorbency obtained from control untreated
cells. 
Cytotoxicity assay for continuous exposure of cells to
drugs and combination of electroporation and drugs 
To determine the sensitivity of HMEC-1 cells to continuous (3
days) exposure to cisplatin or bleomycin, the cells were plated in
96-well microtitre plates and incubated with cisplatin (1.67 to
16.7 mM) or bleomycin (0.1 nM to 10 mM). The sensitivity of the
cells to combined treatments of cisplatin or bleomycin with elec-
tric pulses (electroporation) was determined as described above
for electro-sensitivity, except that the cells were mixed with
cisplatin or bleomycin solution instead of the serum-free D-MEM
at the time of electroporation. One half of the cell suspension was
exposed to electric pulses (1400 V cm–1) and the other half served
as a control for cisplatin or bleomycin treatment alone. The
cisplatin concentrations used were ranging from 16.7 to 670 mM
and the bleomycin concentrations from 0.1 nM to 100 mM. The
cells were exposed to the drugs for 5 min, since this incubation
time was shown to be the optimal, since it allows resealing of
plasma membrane and it does not affect cell viability due to the
evaporation of medium and lack of nutrients (Rols and Teissie,
1998). After that, cells suspension was diluted with D-MEM
supplemented with 10% FCS and plated in 96-well microtitre
plates. The survival of cells treated with electroporation after
exposure to drugs was normalized to electric pulses treatment
alone. The IC50 value (the concentration of cisplatin or bleomycin
that causes 50% reduction in cell survival) was determined for
each treatment group. 
Figure 1 Photograph of the electrodes used in the experiments. The gap
between the electrodes was 2 mm and 50 ml of cell suspension was put
between the electrodes using an automatic pipette Statistical analysis 
Data were tested for normality using Kolmogorov-Smirnov 
test. Data were normally distributed and are therefore represented
as an arithmetic mean ± standard error of the mean. Statistical
analysis was done using SigmaStat statistical software (SPSS Inc). 
RESULTS 
Electro-permeabilization and electro-sensitivity 
In order to determine the optimal electric field intensity, without
significant cytotoxicity, both electro-permeabilization (propidium
iodide) and electro-sensitivity (MTT assay) of HMEC-1 cells were
measured over a range of electric field intensities, which is the crit-
ical parameter for obtaining electro-permeabilization (Figure 2).
Electro-permeabilization of HMEC-1 cells, at an intensity of
1000 V cm–1, was found to induce 30% of cells to be permeabi-
lized. At the highest intensity of 1800 V cm–1 only 85% of cells
were permeabilized. This indicates a relatively high cellular resis-
tance to electroporation although the survival of cells was reduced
to 57% at this intensity. Therefore, 1400 V cm–1 was selected for
the subsequent electrochemotherapy experiments. At this electric
field intensity, only 60% of cells were permeabilized, but the
survival of cells was still approximately 80%. 
Cell survival after continuous exposure of cells to
drugs and combination of electroporation and drugs 
To determine the sensitivity of HMEC-1 cells to cisplatin alone,
cells were continuously exposed to the drug and cell survival
determined after 3 days. Continuous exposure of HMEC-1 cells to
cisplatin resulted in significantly reduced cell survival at doses
higher than 0.67 mM. The IC50 value for cells to cisplatin was 1.8
mM. In experiments using the combination of electroporation and
drugs, the cells were exposed to cisplatin for only 5 min. The IC50
value for cells treated with cisplatin alone was 180 mM (Figure 3).
Exposure of cells to electric pulses increased cisplatin cytotoxicity
10-fold (IC50 value reduced to 18 mM) compared to the IC50 value
of cells exposed to the cisplatin for 5 min. In comparison to cell
survival after continuous exposure to cisplatin, the IC50 value for
the combination of electroporation and drugs (5 min) treated cells
was ~5-times higher. 
The survival of HMEC-1 cells after continuous (3 days) expo-
sure to bleomycin was reduced at the doses higher than 10 nM.
The IC50 value of HMEC-1 cells continuously exposed to
bleomycin was 1 mM. The IC50 value cells treated with bleomycin
for 5 min was 20 mM (Figure 4). The potentiation of bleomycin
cytotoxicity, when cells were exposed to electric pulses was very
high,  ~5000-fold, when compared to the IC50 value of cells
exposed to the bleomycin for 5 min. The IC50 value of cells treated
with combination of electroporation and bleomycin was 4 nM,
which was ~700-fold lower than compared to cells that were
continuously exposed to bleomycin. 
DISCUSSION 
The results of this study demonstrate that electroporation with
cisplatin or bleomycin significantly enhances the cytotoxicity to
Anti-vascular action of electrochemotherapy 567
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Figure 2 Incidence of electro-permeabilization (n ) and electro-sensitivity
(l) in HMEC-1 cells by increasing electroporation field strength. Electro-
permeabilization was measured by propidium iodide uptake, electro-
sensitivity by MTT assay. Data are mean ±1 standard error of the mean
pooled from 3 independent experiments 
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Figure 3 Cell survival after 5 min. (l) exposure of HMEC-1 cells to
cisplatin. In electrochemotherapy protocol (1400 V cm–1), cells were exposed
to the drug for 5 minutes (O). Data are mean ±1 standard error of the mean
pooled from 3 independent experiments
Figure 4 Cell survival after 5 min. (l) exposure of HMEC-1 cells to
bleomycin. In electrochemotherapy protocol (1400 V cm–1), cells were
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exposed to the drug for 5 minutes (O). Data are mean ±1 standard error of
the mean pooled from 3 independent experimentshuman endothelial HMEC-1 cells, even after very short drug 
exposure of cells. It is therefore probable that in vivo elec-
trochemotherapy, especially with bleomycin, may directly damage
the vascular endothelium and account for its antivascular actions,
such as reduced tumour blood flow and infiltration by host blood
cells (Sersa et al, 1999a, b). The antivascular action of electro-
chemotherapy would be in addition to other, non-vascular, mecha-
nisms previously reported (Sersa et al, 1997a, b; Cemazar 
et al, 1999). 
Continuous exposure of human endothelial cells to bleomycin
or cisplatin reduced cell survival substantially in a dose-dependent
manner although this effect was more pronounced with bleomycin
than with cisplatin. In comparison to the IC50 values for several
human and murine tumour cell lines, treated with either of these
drugs (Tables 1 and 2), the values for HMEC-1 cells appear rela-
tively resistant, especially to cisplatin (Lazo et al, 1989; Hait 
et al, 1994; Kambe et al, 1996; Dirix et al, 1997; Cemazar et al,
1998a,b). This is consistent with a report of relatively little anti-
vascular action of cisplatin in vivo (Clements et al, 1999). In
contrast, the present result for bleomycin indicates that HMEC-1
cells show an equal, or enhanced, sensitivity to that reported for
tumour cells with the maximum value of ˜ 200-fold more sensitive
than tumour cell lines (Table 2) (Hait et al, 1994; Dirix et al, 1997;
Cemazar et al, 1998a). At present, only Dirix et al have reported
on the sensitivity of two different endothelial cell lines to
bleomycin (Dirix et al, 1997). In that study, the response of human
umbilical vein endothelial cells (HUVEC) were compared to
HMEC and demonstrated a dose-response in survival with
bleomycin dose. However, the effect was marginal and the IC50 for
both HUVEC and HMEC cells were in the same range shown by
the most resistant tumour cell lines (Table 2). These observations
are in contrast to the present results and probably due to the differ-
ence in endothelial cell lines and also to the reduced proliferation
status (semi-confluent and confluent) of the cultures used to assess
bleomycin cytotoxicity (Dirix et al, 1997) in comparison to the
exponential growth phase used in the present study. 
In the present study, electric pulses were used as a drug delivery
system for bleomycin and cisplatin, which both are reported to
have restricted transport through plasma membrane (Belehradek et
al, 1994; Cemazar et al, 1999). Increased drug uptake and potenti-
ation of cytotoxicity has been demonstrated in vitro for several
tumour cell lines treated with cisplatin, bleomycin, peplomycin
and others, following exposure to electric pulses (Orlowski et al,
1988; Sersa et al, 1995; Kambe et al, 1996; Cemazar et al, 1998a;
Kuriyama et al, 1999). When used in combination with application
of electric pulses the drug dosage can be greatly reduced for 
equivalent or higher cytotoxic effect, compared to drug treatment 
alone (Orlowski et al, 1988; Sersa et al, 1995; Kambe et al, 1996;
Cemazar et al, 1998a; Kuriyama et al, 1999). When electro-
chemotherapy is performed in vivo, the tumour perfusion and
intravascular concentration of the drug are additional factors to be
considered in achieving optimal tumour cytotoxicity. However,
electroporation of solid tumours will also involve treatment of
non-tumour cells within the treatment field, including the endo-
thelial cells lining the tumour vasculature. Our in vitro results
demonstrate that endothelial cells are electroporated at the same
field intensity previously shown to be effective for tumour
cytotoxicity in vivo (Sersa et al, 1995; Miklavcic et al, 1998).
However, compared to the tumour cells in vitro they appeared to
be slightly more resistant to electric pulses (Cemazar et al, 1998c).
The reasons for this are currently unclear. To our knowledge, the
present study is the first report demonstrating the high sensitivity
of human endothelial cells to electroporation with bleomycin and
to lesser extent to electroporation with cisplatin compared to the
tumour cell lines used in the electrochemotherapy protocol (Tables
1, 2). Although the direct comparison of cell sensitivity to the
combination of electroporation and bleomycin or cisplatin would
require that the experiments would be done in the same study,
according to those studies there is some evidence for endothelial
cells being more sensitive to bleomycin than tumour cells. When
electroporation was combined with bleomycin, cell cytotoxicity
was assessed using MTT assay, while clonogenic assay was used
in most of the studies testing combination of electroporation and
cisplatin (Tables 1, 2) (Sersa et al, 1995; Kambe et al, 1996;
Cemazar et al, 1998a). 
The present in vitro data for endothelial cell cytotoxicity are
consistent with our previous demonstration that tumour blood flow
is completely shut down 12 hours after electrochemotherapy with
bleomycin (Sersa et al, 1999b). The severity of the overall antivas-
cular action of electrochemotherapy is likely to be due to a com-
bination of actions mediated at different stages of the cytotoxic
mechanism. For example, the increased uptake of drugs, following
electroporation of plasma membrane, has been demonstrated in
tumour cells, by increased uptake of radioactively labelled
bleomycin and by increased DNA platination (Belehradek et al,
1994; Cemazar et al, 1999). It is unlikely to be cell-specific in vivo
and may account, in part, for the antivascular action of elec-
trochemotherapy. Secondly, the infiltration of host immune cells
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Table 1 IC50 values of tumour and endothelial cell lines treated with cisplatin (continuous exposure) or combination of electroporation and
cisplatin 
Cell line type Cell line (assaya)I C 50(mM) cisplatin IC50 (mM) combination Reference 
Tumour EAT (MTT) 0.4 NDb Cemazar (unpub.) 
SA-1 (clonogenic) 0.9 20.0 Cemazar (unpub.) 
TBL.C12 (clonogenic) 0.18 7.0 Cemazar (unpub.) 
TBL.C12 Pt (clonogenic) 1.5 7.0 Cemazar (unpub.) 
B16 (clonogenic) 1.6 11.0 Sersa et al, 1995 
A253 (Coulter counter) 0.13 ND Lazo et al, 1989 
IGROV 1 (clonogenic) 0.13 20.0 Cemazar et al, 1998b 
IGROV 1/DDP (clonogenic) 2.0 110.0 Cemazar et al, 1998b 
LS174T (MTT) 0.9 40.0 Kambe et al, 1996 
Endothelial HMEC-1 (MTT) 12.0 40.0 Present study 
aAssay used to assess cell cytotoxicity. b Not determined. Anti-vascular action of electrochemotherapy 569
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into the tumour has been shown to be responsible for a degree of
tumour cytotoxicity, as evidenced by the change in tumour
response to electrochemotherapy applied in immunodeficient
animals (Sersa et al, 1997a). Overall, the changes in endothelial
function and survival are not unexpected, in relation to tumour cell
response, and are consistent with the observed changes in tumour
blood flow, as measured using 86RbCl extraction and Patent Blue
technique (Sersa et al, 1999a,b). 
The finding that electrochemotherapy has an antivascular 
action is important since it could identify other approaches to
increase the effectiveness of electrochemotherapy treatment of
tumours. Electrochemotherapy is being investigated in several
trials on cancer patients. Clinical studies on accessible tumour
nodules of different tumour types, such as malignant melanoma,
basal cell carcinoma, squamous cell carcinoma, adenocarcinoma
and others have demonstrated that electrochemotherapy with both,
bleomycin or cisplatin is very effective, resulting in high incidence
of complete responses (Heller et al, 2000). At present, a major
limitation to this treatment is its applicable to small (< 10 mm
diameter) cutaneous and subcutaneous nodules that can be placed
between the electrodes. This limitation can be overcome by either
repetitive application so that the whole tumour area is covered, or
by repeating the therapy on any residual tumour mass or by the use
of needle electrodes that enable better distribution of the electric
field within each tumour (Gilbert et al, 1997; Heller et al, 2000). 
It is now clear that improvements in outcome of electro-
chemotherapy could potentially be achieved by exploiting its anti-
vascular action. Electrochemotherapy could be applied to blood
vessels that supply the tumours, if accessible, and achieve cessa-
tion of blood supply similar to vascular embolization, a technique
already in practice (Acunas and Rozanes, 1999). Intra-arterial
injection of either bleomycin or cisplatin, into the vessel supplying
the tumour, immediately before electroporation of the tumours
would spare the systemic cytotoxicity of the drug because the drug
dose used for electrochemotherapy could be reduced relative to the
intravenous or intratumour dose necessary for the same tumour
effect. These two approaches would exploit the advantages associ-
ated with anti-vascular strategies; namely, that the incidence of
damaged endothelial cells would result in cessation of flow to an
entire vessel segment, consequently enhancing cytotoxicity of
tumour cells (Denekamp, 1990). 
In conclusion, our demonstration that electroporation with
cisplatin or bleomycin is highly cytotoxic for a human endothelial
HMEC-1 cell provides evidence for a potential mechanism which
explains the observed antivascular actions of electrochemo-
therapy. Future studies to identify the determinants of endothelial
response, and their relationship to antivascular action, will result
in increased cytotoxicity by electrochemotherapy. 
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